Custom-made trays for targeted treatment of oral vesiculobullous diseases: A proposed protocol.


Journal

Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070

Informations de publication

Date de publication:
11 2020
Historique:
received: 10 09 2020
revised: 08 10 2020
accepted: 18 10 2020
pubmed: 27 10 2020
medline: 9 3 2021
entrez: 26 10 2020
Statut: ppublish

Résumé

Topical and intralesional corticosteroids (CS) are effective treatments for oral manifestations of autoimmune vesiculobullous diseases (VBD); however, may cause unnecessary absorption in the adjacent healthy mucosal surfaces, local infections, atrophy, and injection pain. To propose a protocol using a unique modality for targeted administration of CS for the treatment of local manifestations of oral VBD. The medical records of nine patients with systemic CS-resistant VBD oral lesions, were reviewed following 3 weeks of treatment and 3 months of tapering using a custom-made tray designed for precise application of topical CS targeted to the involved mucosa. Following treatment, lesions have healed in 8/9 patients. Involvement of surrounding mucosa was minimal, and no systemic adverse effects were recorded. The proposed protocol using custom-made trays for targeted CS treatment could be an effective alternative treatment for oral VBD.

Identifiants

pubmed: 33105060
doi: 10.1111/dth.14446
doi:

Substances chimiques

Adrenal Cortex Hormones 0
Glucocorticoids 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e14446

Informations de copyright

© 2020 Wiley Periodicals LLC.

Références

Baum S, Sakka N, Artsi O, Trau H, Barzilai A. Diagnosis and classification of autoimmune blistering diseases. Autoimmun Rev. 2014;13(4-5):482-489. https://doi.org/10.1016/j.autrev.2014.01.047.
Fleming TE, Korman NJ. Cicatricial pemphigoid. J Am Acad Dermatol. 2000;43(4):571-591; quiz 591-4. https://doi.org/10.1067/mjd.2000.107248.
Kiran MS, Vidya S, Aswal GS, Kumar V, V. R. Systematic topical steroids in the management of oral mucosal lesions. J Pharm Bioallied Sci. 2017;9(suppl 1):S1-S3. https://doi.org/10.4103/jpbs.JPBS_91_17.
Lozada-Nur F, Miranda C, Maliksi R. Double-blind clinical trial of 0.05% clobetasol propionate (corrected from proprionate) ointment in orabase and 0.05% fluocinonide ointment in orabase in the treatment of patients with oral vesiculoerosive diseases. Oral Surg Oral Med Oral Pathol. 1994;77(6):598-604. https://doi.org/10.1016/0030-4220(94)90318-2.
Scully C, Beyli M, Ferreiro MC, et al. Update on oral lichen planus: etiopathogenesis and management. Crit Rev Oral Biol Med. 1998;9(1):86-122. https://doi.org/10.1177/10454411980090010501.
Joly P, Roujeau JC, Benichou J, et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med. 2002;346(5):321-327. https://doi.org/10.1056/NEJMoa011592.
Gonzalez-Moles MA, Scully C. Vesiculo-erosive oral mucosal disease-management with topical corticosteroids: (1) fundamental principles and specific agents available. J Dent Res. 2005;84(4):294-301. https://doi.org/10.1177/154405910508400401.
Kassem R, Yarom N, Scope A, Babaev M, Trau H, Pavlotzky F. Treatment of erosive oral lichen planus with local ultraviolet B phototherapy. J Am Acad Dermatol. 2012;66(5):761-766. https://doi.org/10.1016/j.jaad.2011.04.017.
Carbone M, Conrotto D, Carrozzo M, Broccoletti R, Gandolfo S, Scully C. Topical corticosteroids in association with miconazole and chlorhexidine in the long-term management of atrophic-erosive oral lichen planus: a placebo-controlled and comparative study between clobetasol and fluocinonide. Oral Dis. 1999;5(1):44-49. https://doi.org/10.1111/j.1601-0825.1999.tb00063.x.
Gelfand JM, Werth VP. Treatment of bullous pemphigoid with topical corticosteroids: review of a randomized controlled trial. Arch Dermatol. 2002;138(9):1236-1237. https://doi.org/10.1001/archderm.138.9.1236.
Kassem R, Peretz A, Porat Ben Amy D. Topical paromomycin for treating solitary mucosal leishmaniasis. Int J Dermatol. 2018;57(6):721-723. https://doi.org/10.1111/ijd.13930.

Auteurs

Dalit Porat Ben Amy (D)

Oral Medicine Unit, Department of Oral and Maxillofacial Surgery, Baruch Padeh Medical Center, Poria, Israel.
Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.

Riad Kassem (R)

Department of Dermatology, Sheba Medical Center, Ramat Gan, Israel.
Sackler faculty of medicine, Tel Aviv University, Tel Aviv, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH